User 15314582's  Instablog

User 15314582
Send Message
  • Little Known Canadian Biotech Ready For Take-Off! 4 comments
    Jan 5, 2014 2:20 PM | about stocks: ICOTF

    ICo Therapeutics Ltd. (TSXV:ICO) ICo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. ICo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases.

    With the recent significant news that the Company's U.S. patent 8,592,382 was issued for the Oral Amphotericin B platform (Oral AmpB) providing protection around oral delivery of the drug, excitement and anticipation is building! With the recent receipt of ethics approval, the Oral AmpB technology is also moving into in vitro testing with study partners in Montreal, and will examine the role of this formulation in targeting latent HIV reservoirs which remain in individuals despite enormous therapeutic advances in the treatment of HIV/AIDS. ICo is poised to start making licensing announcements with major pharmaceutical companies across the globe. These are milestones which biotech analysts have been expecting for years.

    The good news is that there still seems to be a bit of time to get in before the next major milestone achievements happen. The first big announcement should involve the successful results of the Phase 2 trials, expected in March or April 2014. That the company has just started trading on the prestigious OTCQX does not seem to be a coincidence in any way at all. In fact, insiders suggest this is a deliberate move to gain traction in the US markets before the major announcements are made!

    And from the company's website, check out this excitement either completed or about to be completed:


    iCo-007 for Diabetes Related Blindness

    33 Phase 1 trial complete with encouraging efficacy trends

    33 Complete "fill finish" manufacturing program to produce clinical supply

    33 Phase 2 clinical trial in the U.S. initiated

    33 Phase 2 Research Collaboration with JDRF

    33 Phase 2 iDEAL study clinical update

    ❑ Phase 2 iDEAL study primary endpoint

    ❑ Phase 2 iDEAL study secondary endpoints

    ❑ Ongoing regional partnership discussions

    iCo-008 for Sight Threatening Diseases

    33 License systemic rights to Immune Pharma for $32 million+

    ❑ Pursuing non-dilutive funding for ocular programs

    Oral Amphotericin B Delivery System

    33 FDA Pre-IND meeting - iCo has plan to move forward

    33 Orphan Drug Status received for Visceral Leishmaniasis

    33 Approximately $2 million in non-dilutive funding received

    (CPDD/Gates Foundation and CIHR)

    33 Robust Scientific Advisory Board Assemble

    ❑ In vitro testing in Q2 2013

    ❑ Ongoing partnership discussions

    Add to any of these licensing agreements a surprise news announcement or two, combined with competing large pharmaceuticals wanting to license the same technology so as not to fall behind the competition and ICo Therapeutics could be the one that gets away. Don't risk missing this! Take a flier on ICo Therapeutics soon! This could be the next ten-bagger in the making! ICo Therapeutics has been silently going about its work and very soon will be a name everyone is talking about. Do NOT pass up the chance of a lifetime!

    Disclosure: I am long ICOTF, .

    Stocks: ICOTF
Back To User 15314582's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (4)
Track new comments
  • lemmema2
    , contributor
    Comments (24) | Send Message
    I am actually watching $ICOTF since a while because of the science. In the article you stated it might be a ten-bagger. I am not so sure about that, they have a lot to achieve to be even recognized by the market. Also your milestones list does not include a single date, could you update the milestones with dates? That would help,
    thanks martin
    5 Jan 2014, 07:52 PM Reply Like
  • makingmoneynow
    , contributor
    Comments (2) | Send Message
    I am long ICOTF and I suggest that if you are considering a multi-bagger potential, this is one of the stories that will soon become hot in both the US and Canada.


    The Company reported that primary data for 110+ patients will come in March/April of this year and secondary data comes in August/September. The Company has a collaboration agreement with the JRDF, whereby JRDF is bearing 40% of the trial cost. 30% of the shares are locked between ISIS (NASDAQ multi billion dollar Co: ISIS), 10% with Special Science Fund (US) and c. 9.7% is with insiders.


    In addition, the Company has a 6% stake in Immune Pharmaceuticals (IMNP on the Nasdaq), which is undertaking Ph2 trial and will be reporting results this year as well. ICo will get milestone payments from Immune along the way with a total potential milestones of 32 million dollars (yes more than ICOTF's current market cap).


    Last but not least, dosing for the first 8 patients from 009 is due in H1 of this year as well.


    Company has enough cash till June 2014 and has enough warrants to get it through 2+ years if results of its 007 are positive.


    Targets by analysts in Canada ranged from 1.05$ to 4$ only on 007 results.


    Have a look at the presentation as it should address your questions.


    Happy to answer further questions,

    6 Jan 2014, 06:57 AM Reply Like
  • lemmema2
    , contributor
    Comments (24) | Send Message
    thanks man, i bought 10k shares, and I am praying for positive DME clinical trial results :)
    10 Apr 2014, 07:07 PM Reply Like
  • kr8008st
    , contributor
    Comment (1) | Send Message
    POS stock!
    13 May 2014, 08:57 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.